Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. - Wikidata - wikimedia - TriplyDB

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

http://www.wikidata.org/entity/Q33932779

about

Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers Targeted diphtheria toxin to treat BPDCN.Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice Immunogenicity of therapeutic recombinant immunotoxins.Immunotoxin Therapy for Lung Cancer.Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.B-cell subsets, signaling and their roles in secretion of autoantibodies.Chemical JAK inhibitors for the treatment of rheumatoid arthritis.

P2860

Q26751473-C2088312-DD68-45E4-988C-E8E4ABE252E1 Q33917153-F0FFAA84-9680-47B9-9193-CD5C518D0A09 Q35070412-23DBBEDC-E5D6-4DC1-9ECF-D8DE275E6EE2 Q36593468-78F9BEC7-9471-4C4B-9DB0-20F8518873E6 Q37684156-580FEFFC-1ED8-4587-8467-FFDD2F3B6BD4 Q38778443-F4CBC589-A6A3-49BC-A203-192471D9BA9D Q38837769-5A2DA48F-1222-4BBD-8BE9-3C36B6486BDC Q38851433-58AA6200-ADF2-470F-8521-9261DEA1F5C0 Q38941577-7D6D13EB-DD4A-406C-A54B-14A6292C458B Q47222860-C5FE1767-FE8A-4991-A301-D3D551549EAF Q50645188-0C7E6004-DFA1-4CB7-A65B-8D411A62C8E2 Q54172510-E23F39C4-4CFA-4655-9510-1FBD7CD88836

P2860

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

http://www.wikidata.org/entity/Q33932779

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

@ast

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

@en

type

label

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

@ast

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

@en

prefLabel

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

@ast

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

@en

P1433

Q33932779-4629D273-E90A-4CD5-82CA-7B24C2794963

P1476

Q33932779-0D695F64-440B-4654-9F0A-979485E6852F

P2093

Q33932779-08D7A7EE-D28F-49DF-953C-183388AA290B

Q33932779-7657766D-5235-4D47-924B-6672EDE94176

Q33932779-92B33B0E-B953-4D89-848C-27E8E3FB982E

Q33932779-C079163E-7DE8-4F5C-9BA2-1C988F50D47B

Q33932779-C3A4EC81-68F9-44D4-BD86-221465215F69

Q33932779-E3AE66B5-E13D-4C00-9DE7-F82B32CD8297

P2860

Q33932779-04C520EB-221E-45CF-B784-6AC14369ACBA

Q33932779-091E4680-08BD-48A4-9853-E5C2627F67A6

Q33932779-1273DBD6-7922-4493-BF76-0DC2D63AA161

Q33932779-127C1AF3-BCF9-44E3-A095-866248C54257

Q33932779-18843DBE-7501-49FD-9A39-0CD407B5E64B

Q33932779-1F2FA45C-55DC-4A09-828B-7EF842631A6D

Q33932779-26550FE3-DA71-4031-96B5-906F8558E3A1

Q33932779-306EEF06-AB36-4ADA-963E-91B2ECDB7D8C

Q33932779-335DCC5D-E95B-48E1-91A2-A6CAF41492B7

Q33932779-366ECA98-49D2-4E91-B1A1-A5B4B4BCF67C

P304

Q33932779-6DD251C8-132C-4533-A0FB-97755DB9F307

P31

Q33932779-F1153910-0B85-4251-B3CD-CC2B3929CBE9

P356

Q33932779-0A1444C9-1B08-4345-A29A-EB694EA3BDA2

P407

Q33932779-005D891F-729B-4BBF-85E5-3177743B4D0B

P433

Q33932779-01774AF8-8C22-4921-ACC4-FCE12C1A0EFF

P478

Q33932779-D4D6D388-9D26-4A43-A183-AEE4EE073C6C

P50

Q33932779-FDB7EA24-D770-4E01-A4D7-6D8D597B7218

P577

Q33932779-3A5452BE-1A6F-4CA5-9405-AF8CC79F08DE

P5875

Q33932779-F8B4E6E8-75CA-47D8-A21B-FEB622A9AD14

P698

Q33932779-2F099FAE-442E-474A-BAA1-5D2C99BC262F

P932

Q33932779-EEBC9664-5356-485E-8096-E3985663B0C5

P356

JIMMUNOL.1400063

P1433

Journal of Immunology

P1476

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts

@en

P2093

Craig Thomas

http://www.w3.org/2001/XMLSchema#string

David J FitzGerald

http://www.w3.org/2001/XMLSchema#string

Ira H Pastan

http://www.w3.org/2001/XMLSchema#string

John J O'Shea

http://www.w3.org/2001/XMLSchema#string

Kamran Ghoreschi

http://www.w3.org/2001/XMLSchema#string

Masanori Onda

http://www.w3.org/2001/XMLSchema#string

P2860

Janus kinases in immune cell signaling

Selectivity and therapeutic inhibition of kinases: to be or not to be?

Therapeutic targeting of Janus kinases

Stats: transcriptional control and biological impact

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma.

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.

Microenvironmental niches in the bone marrow required for B-cell development.

P304

48-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.1400063

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

193

http://www.w3.org/2001/XMLSchema#string

P50

Scott M Steward-Tharp

P577

2014-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262812845

http://www.w3.org/2001/XMLSchema#string

P698

24890727

http://www.w3.org/2001/XMLSchema#string

P932

4106678

http://www.w3.org/2001/XMLSchema#string